Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Barbotage vs Barbotage with Cortisone for Calcific Tendonitis
NCT04126278Phase 4Terminated
- Sponsor
- NYU Langone Health
- Start
- Dec 2020
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial (2 arms), sponsored by NYU Langone Health. Primary endpoints: Visual Analog Scale Score at Month 6, QuickDASH Score at Month 6 and 2 more. Started Dec 2020; status: terminated.
Beyond the preview
Go deeper on NCT04126278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126278.